Detail akcie Profusa Rg online

Business Summary: Profusa, Inc. is a digital health company developing tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its injectable and biosensors and its intelligent data platform, the Company is focused on providing people with a personalized biochemical signature. Its offering in the European Union, the Lumee Oxygen Platform, monitors tissue oxygen levels and is intended for applications such as peripheral artery disease, chronic wounds (including diabetic ulcers and pressure sores), and reconstructive surgery. Its research and development efforts are primarily focused on the Lumee Glucose Platform, a continuous glucose monitor (CGM) consisting of a biocompatible gel injected under the skin that monitors interstitial glucose levels for several months from a single injection. Its Data Discovery Platform, built on NVIDIA AI, transforms the continuous stream of biochemical sensor data into personalized clinical insights.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Profusa Inc revenues was not reported. Net loss increased from $1.1M to $31.5M. Higher net loss reflects Gain on change in fair value of warrant increase from $496K to $5.4M (expense), Change in fair value of convertible prom decrease from $141K (income) to $1.1M (expense), Formation and operating costs increase of 49% to $1.6M (expense).